COVID-19 の重症患者 5 人を回復期プラズマで治療
Chenguang Shen1, Zhaoqin Wang1, Fang Zhao1
1Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
回復期のプラズマ輸血は,ARDSの重症なCOVID-19患者の臨床状態を改善しました. この予備的な研究は,治療の有効性に関するさらなる臨床試験を正当化するために,潜在的な利益を示唆しています.
科学分野:
- 感染症
- 免疫学
- クリティカル ケア 医療
背景:
- 2019年新型コロナウイルス病 (COVID-19) は,高い死亡率と限られた治療法で,世界的な健康問題となっています.
- 重度のCOVID-19の効果的な治療法の開発は,特に急性呼吸器障害症候群 (ARDS) の患者にとって非常に重要です.
関連する概念動画
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Continuous Renal Replacement Therapy


